Committee On Devices, Biologics, and Technology

Mission

Influence all aspects of orthopaedic devices, biologics, and technologies with respect to regulatory, industrial and payors affairs. Provide the fellowship with evidence-based resources, quality, and value assessments to distill the current state of evidence and equip membership with resources of which assist with making informed decisions, facilitating the safe and effective use of devices, biologics, and technologies to treat musculoskeletal disorders in patients.

Charges

  1. Align all activities to support execution and achievement of the mission, vision, goals, strategic objectives and metrics of the Strategic Plan and conduct all business in accordance with the Core Values as adopted by the Board of Directors.
  2. Align progress in aspects of orthopaedic technology with improvements in quality and value for patients, surgeons, and society.
  3. Monitor and shape regulatory, industrial and payor policy in orthopaedic technology including biologics, medical devices, pharmaceutical products, informatics, analytics and artificial intelligence, machine learning, regenerative medicine, cellular & tissue therapies, combination products, imaging & robotics, tissue grafts, operating room equipment, and related technology in orthopaedic surgery.
  4. Promote registry data to clarify patient outcomes, optimize value in musculoskeletal care, and inform treatment decisions.
  5. Develop interactive and multimedia educational tools for orthopaedic technology.
  6. Collaborate with other AAOS committees including the: Evidence-Based Quality and Value Committee; Patient Safety Committee; Coding, Coverage, and Reimbursement Committee; and Healthcare Systems Committee. Provide a seamless member experience and actively foster diversity and innovation within the AAOS governance structure.
  7. Collaborate with non-AAOS specialty societies, FDA and other regulatory bodies. Collaborate with standards and professional organizations such as ASTM and the American Association of Tissue Banks. Interact with industry bodies including OSMA, AdvaMed, MDMA, and others.

Reporting Relationship

Reports to the Council on Research and Quality

Composition

Chair

Eight (8) At-Large Members

One (1) ASTM/ISO Representative

One (1) American Association of Tissue Banks Representative

Three (3) Consultants including other professional society representatives

Term of Office

For chair, two (2) years; eligible for one (1) additional two (2) year term.

For members-at-large, two (2) years; eligible for one (1) additional two (2) year term.

Staff Liaison (title)

Senior Manager, Clinical Quality and Value Development

 

Last Updated: 6/15/2021

(7882)